Selenium — Expert Claims
Extracted from publicly available podcast transcripts and videos. Each claim is attributed and sourced.
Claims are extracted using AI (Claude) from publicly available transcripts and manually reviewed. Extraction confidence (high / medium / low) indicates accuracy of capture. Each claim is compared against PubMed research.
24 expert mentions
"For supplementation, 50 to 200 micrograms per day appears safe."
For supplementation, 50 to 200 micrograms per day appears safe.
"For supplementation, 50 to 200 micrograms per day appears safe."
For supplementation, 50 to 200 micrograms per day appears safe.
None of the 10 published studies provided contain extractable key findings, populations, or limitations data, making it impossible to directly evaluate the claim that 50–200 mcg/day of selenium is a safe supplementation range. While the studies span relevant areas (thyroid conditions, sperm quality, immunity, HIV, IVF), their listed key findings are all null, preventing any direct comparison. The claim itself aligns with widely cited tolerable upper intake levels (the NIH sets the UL at 400 mcg/day for adults), but this cannot be confirmed or denied based solely on the research abstracts provided here.
"Selenomethionine is the most bioavailable form."
Selenomethionine is the most bioavailable form of selenium for supplementation.
"Selenomethionine is the most bioavailable form."
Selenomethionine is the most bioavailable form of selenium for supplementation.
None of the 10 provided studies directly compare selenomethionine to other selenium forms (e.g., selenite, selenate, selenium yeast) in terms of bioavailability. The studies listed focus on clinical outcomes in specific populations (Graves' orbitopathy, thyroid disorders, HIV, fertility, ME/CFS) or general selenium status and immunity, and none report key findings that address the bioavailability question. While selenomethionine's superior bioavailability is a widely cited claim in nutritional biochemistry literature, the specific evidence base provided here does not contain data to support, partially support, or contradict this claim.
"Brazil nuts are the most concentrated dietary source — just one or two per day can meet selenium requirements, though the selenium content varies dramatically based on soil selenium content. This makes food-based selenium intake unreliable."
Brazil nuts are the most concentrated dietary source of selenium, with just one or two per day able to meet selenium requirements, though selenium content varies dramatically based on soil selenium content, making food-based intake unreliable.
None of the 10 provided studies directly address Brazil nuts as a dietary selenium source, soil-dependent selenium variability, or the adequacy of 1-2 Brazil nuts per day for meeting selenium requirements. The studies focus on selenium supplementation in clinical contexts (Graves' orbitopathy, Hashimoto's thyroiditis, HIV, fertility, obesity) rather than food-based selenium intake or Brazil nut selenium content. While the expert's claim is well-established in nutritional science literature, the specific PubMed references provided here offer no direct evidentiary basis to support or contradict it.
"The Nutritional Prevention of Cancer trial showed a 50% reduction in prostate cancer incidence with selenium supplementation."
The Nutritional Prevention of Cancer trial showed a 50% reduction in prostate cancer incidence with selenium supplementation.
"Brazil nuts are the most concentrated dietary source — just one or two per day can meet selenium requirements, though the selenium content varies dramatically based on soil selenium content. This makes food-based selenium intake unreliable."
Brazil nuts are the most concentrated dietary source of selenium, with just one or two per day able to meet selenium requirements, though selenium content varies dramatically based on soil selenium content, making food-based intake unreliable.
"the subsequent large SELECT trial found no benefit and a possible harm at higher doses."
The subsequent large SELECT trial found no benefit from selenium supplementation and a possible harm at higher doses.
None of the 10 provided studies address the SELECT (Selenium and Vitamin E Cancer Prevention Trial) or its findings on selenium supplementation and cancer prevention. The provided literature focuses on selenium in contexts such as thyroid conditions, HIV, sperm quality, and IVF — not the large-scale cancer prevention outcomes that the SELECT trial examined. While the SELECT trial is a well-known, real published RCT (Lippman et al., JAMA 2009) and Dr. Patrick's characterization of it is broadly accurate in the scientific literature, the evidence base provided here contains no studies that directly confirm or contradict this specific claim.
"Keshan disease — a cardiomyopathy endemic to parts of China with selenium-poor soil — is one of the clearest examples of a deficiency disease caused by a trace mineral."
Keshan disease, a cardiomyopathy endemic to parts of China with selenium-poor soil, is one of the clearest examples of a deficiency disease caused by a trace mineral.
None of the 10 provided PubMed studies address Keshan disease, selenium-deficient soil in China, or endemic cardiomyopathy caused by selenium deficiency. The retrieved literature focuses on selenium supplementation in contexts such as Graves' orbitopathy, Hashimoto's thyroiditis, HIV, sperm quality, and IVF — none of which directly test or evaluate the claim about Keshan disease. While Keshan disease is well-established in the broader scientific literature as a selenium-deficiency cardiomyopathy, the specific evidence base provided here cannot be used to support or contradict the claim.
"The Nutritional Prevention of Cancer trial showed a 50% reduction in prostate cancer incidence with selenium supplementation."
The Nutritional Prevention of Cancer trial showed a 50% reduction in prostate cancer incidence with selenium supplementation.
None of the 10 provided PubMed studies address the Nutritional Prevention of Cancer (NPC) trial or prostate cancer incidence with selenium supplementation. The retrieved literature focuses on unrelated topics such as IVF, thyroid conditions (Graves' orbitopathy, Hashimoto's thyroiditis), sperm quality, HIV, and metabolic rate — none of which are relevant to evaluating the specific claim about a 50% reduction in prostate cancer. Without direct evidence from the NPC trial or related prostate cancer selenium studies in the provided corpus, no comparison can be made.
"Selenium deficiency is associated with thyroid dysfunction, impaired immune response, reduced male fertility, and increased cancer risk in epidemiological studies."
Selenium deficiency is associated with thyroid dysfunction, impaired immune response, reduced male fertility, and increased cancer risk in epidemiological studies.
The expert's claim spans four distinct health domains (thyroid dysfunction, immune response, male fertility, and cancer risk), and the retrieved literature touches on some of these areas but provides no extractable key findings, populations, or limitations for any of the 10 studies. The study types present (systematic reviews and meta-analyses on thyroid conditions like Hashimoto's and Graves' orbitopathy, a systematic review on selenium and immunity, and a meta-analysis on sperm quality) are broadly consistent with the claim's scope and represent higher-quality evidence designs, suggesting the claim is biologically plausible and partially corroborated by the existence of this literature. However, the claim specifically references 'epidemiological studies' for cancer risk associations, and no epidemiological or cancer-focused study appears in the provided evidence base. Because no actual key findings, effect sizes, or population data were extractable from any study, direct confirmation or contradiction of the specific claim cannot be established from this evidence set alone.
"selenium is protective in selenium-deficient populations but not helpful — and potentially harmful — in selenium-replete populations. This inverted-U dose-response relationship is important."
Selenium is protective in selenium-deficient populations but not helpful — and potentially harmful — in selenium-replete populations, reflecting an inverted-U dose-response relationship.
None of the 10 provided studies contain extractable key findings, populations, or limitations data that directly address the inverted-U dose-response relationship between selenium status and health outcomes. While the studies span relevant topics (thyroid conditions, immunity, HIV, sperm quality), the absence of reported findings makes it impossible to confirm or refute the claim using this evidence base. The claim itself is biologically plausible and aligns with well-established selenium pharmacology, but the provided research corpus does not furnish direct evidence to support or contradict it.
"Keshan disease — a cardiomyopathy endemic to parts of China with selenium-poor soil — is one of the clearest examples of a deficiency disease caused by a trace mineral."
Keshan disease, a cardiomyopathy endemic to parts of China with selenium-poor soil, is one of the clearest examples of a deficiency disease caused by a trace mineral.
"selenium is protective in selenium-deficient populations but not helpful — and potentially harmful — in selenium-replete populations. This inverted-U dose-response relationship is important."
Selenium is protective in selenium-deficient populations but not helpful — and potentially harmful — in selenium-replete populations, reflecting an inverted-U dose-response relationship.
"the subsequent large SELECT trial found no benefit and a possible harm at higher doses."
The subsequent large SELECT trial found no benefit from selenium supplementation and a possible harm at higher doses.
"Selenium deficiency is associated with thyroid dysfunction, impaired immune response, reduced male fertility, and increased cancer risk in epidemiological studies."
Selenium deficiency is associated with thyroid dysfunction, impaired immune response, reduced male fertility, and increased cancer risk in epidemiological studies.
"The most important selenoproteins include the glutathione peroxidase family — which reduce hydrogen peroxide and lipid hydroperoxides using glutathione — and thioredoxin reductase, which is central to cellular redox regulation."
The glutathione peroxidase family of selenoproteins reduces hydrogen peroxide and lipid hydroperoxides using glutathione, and thioredoxin reductase is central to cellular redox regulation.
The expert's claim describes well-established biochemical mechanisms — glutathione peroxidase (GPx) reducing hydrogen peroxide and lipid hydroperoxides via glutathione, and thioredoxin reductase's role in redox regulation — which are foundational selenoprotein biochemistry. However, none of the 10 retrieved studies directly address or test these mechanistic claims; they focus on clinical outcomes of selenium supplementation in populations such as Graves' orbitopathy, Hashimoto's thyroiditis, HIV, infertility, and ME/CFS. Because the provided literature does not contain mechanistic biochemistry studies evaluating GPx or thioredoxin reductase enzyme activity and function, the evidence base cannot be used to directly support or contradict the claim.
"The most important selenoproteins include the glutathione peroxidase family — which reduce hydrogen peroxide and lipid hydroperoxides using glutathione — and thioredoxin reductase, which is central to cellular redox regulation."
The glutathione peroxidase family of selenoproteins reduces hydrogen peroxide and lipid hydroperoxides using glutathione, and thioredoxin reductase is central to cellular redox regulation.
"Selenium is a trace mineral incorporated into proteins as selenocysteine — sometimes called the 21st amino acid — and it's essential for a group of proteins called selenoproteins that play critical roles in antioxidant defense, thyroid hormone metabolism, and DNA synthesis."
Selenium is a trace mineral incorporated into proteins as selenocysteine, sometimes called the 21st amino acid, and is essential for selenoproteins that play critical roles in antioxidant defense, thyroid hormone metabolism, and DNA synthesis.
"Selenium is also required for the synthesis and activation of thyroid hormones, specifically the conversion of T4 to the active T3 form by deiodinase enzymes."
Selenium is required for the synthesis and activation of thyroid hormones, specifically the conversion of T4 to the active T3 form by deiodinase enzymes.
The expert's claim describes a well-established biochemical mechanism — that selenoprotein deiodinase enzymes catalyze the conversion of thyroxine (T4) to the active triiodothyronine (T3). However, none of the 10 provided studies directly address or report on this specific mechanistic claim. The studies cover areas such as Graves' orbitopathy (PMIDs 38374579, 39138905), Hashimoto's thyroiditis (PMID 39698034), sperm quality (PMID 30462179), and general selenium biology, but none provide key findings or data that can be directly compared against the deiodinase-mediated T4-to-T3 conversion claim. The absence of reported key findings across all studies further limits any meaningful comparison.
"Selenium is a trace mineral incorporated into proteins as selenocysteine — sometimes called the 21st amino acid — and it's essential for a group of proteins called selenoproteins that play critical roles in antioxidant defense, thyroid hormone metabolism, and DNA synthesis."
Selenium is a trace mineral incorporated into proteins as selenocysteine, sometimes called the 21st amino acid, and is essential for selenoproteins that play critical roles in antioxidant defense, thyroid hormone metabolism, and DNA synthesis.
The expert's claim is a well-established biochemical/mechanistic statement about selenium's incorporation as selenocysteine (the 21st amino acid) and its roles in antioxidant defense, thyroid hormone metabolism, and DNA synthesis. While none of the provided studies directly test or confirm these molecular mechanisms, the claim reflects consensus biochemistry rather than a novel assertion requiring RCT validation. The available studies (RCTs on thyroid conditions, systematic reviews on immunity and supplementation) address clinical outcomes of selenium supplementation rather than the underlying biochemical mechanisms described. Mechanistic claims of this nature are typically validated through biochemistry and molecular biology literature, not the clinical trial designs represented here.
"Selenium is also required for the synthesis and activation of thyroid hormones, specifically the conversion of T4 to the active T3 form by deiodinase enzymes."
Selenium is required for the synthesis and activation of thyroid hormones, specifically the conversion of T4 to the active T3 form by deiodinase enzymes.
"Testing blood selenium or selenium via red blood cell testing before supplementing is worthwhile given the narrow therapeutic window."
Testing blood selenium or selenium via red blood cell testing before supplementing is worthwhile given selenium's narrow therapeutic window.
"Testing blood selenium or selenium via red blood cell testing before supplementing is worthwhile given the narrow therapeutic window."
Testing blood selenium or selenium via red blood cell testing before supplementing is worthwhile given selenium's narrow therapeutic window.
None of the 10 provided studies directly address the value of pre-supplementation blood or red blood cell selenium testing as a clinical practice. While several studies (e.g., PMIDs 37513551, 38374579, 39138905) involve selenium supplementation in various populations, none of their reported findings speak to baseline testing protocols or the practical utility of measuring selenium status before supplementing. The claim about selenium's narrow therapeutic window is a well-established pharmacological principle referenced in toxicology literature, but the provided evidence base does not contain studies that directly validate or refute the specific recommendation to test first.